BNP Paribas Financial Markets Invests $43,000 in CeriBell (NASDAQ:CBLL)

BNP Paribas Financial Markets purchased a new position in shares of CeriBell (NASDAQ:CBLL) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,667 shares of the company’s stock, valued at approximately $43,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Legal & General Group Plc purchased a new stake in shares of CeriBell during the fourth quarter worth about $32,000. Summit Investment Advisors Inc. purchased a new stake in CeriBell in the fourth quarter valued at approximately $33,000. Tower Research Capital LLC TRC purchased a new stake in CeriBell in the fourth quarter valued at approximately $37,000. PNC Financial Services Group Inc. purchased a new stake in CeriBell in the fourth quarter valued at approximately $47,000. Finally, Corebridge Financial Inc. purchased a new stake in CeriBell in the fourth quarter valued at approximately $158,000.

Insider Transactions at CeriBell

In other news, CEO Xingjuan Chao sold 25,000 shares of the business’s stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $16.96, for a total transaction of $424,000.00. Following the transaction, the chief executive officer now directly owns 727,151 shares of the company’s stock, valued at approximately $12,332,480.96. The trade was a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 49,700 shares of company stock valued at $796,434. Corporate insiders own 20.10% of the company’s stock.

CeriBell Stock Down 1.5%

Shares of CBLL stock opened at $16.93 on Wednesday. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The firm’s 50 day moving average price is $16.69 and its two-hundred day moving average price is $21.57.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. Analysts expect that CeriBell will post -2.46 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CBLL. Canaccord Genuity Group restated a “buy” rating and issued a $33.00 target price on shares of CeriBell in a report on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a report on Friday, April 4th. They issued a “buy” rating and a $32.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $32.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.